Skip to content

OPIANT PHARMACEUTICALS, INC.: 10-Q filed 2014-03-17

What OPIANT PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-03-17 (fiscal Q2 2014): 20 published measures, 78 facts as tagged in accession 0001144204-14-015949.

This filing

Form
10-Q (quarterly report)
Filed
2014-03-17
Fiscal period
fiscal Q2 2014
Accession
0001144204-14-015949 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OPIANT PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-01-31447,172USD
At 2013-07-31643,053USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-01-312,149,026USD
At 2013-07-311,633,069USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-01-31-1,701,854USD
At 2013-07-31-990,016USD
At 2012-07-31-618,718USD
At 2011-07-31-338,517USD
At 2010-07-31-637,287USD
At 2009-07-31290USD
At 2008-07-31-28,154USD
At 2007-07-31-10,230USD
At 2006-07-3123,375USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-01-31420,428USD
At 2013-07-31598,623USD
At 2013-01-31151,700USD
At 2012-07-3120,423USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-11-01 to 2014-01-31-5,055,113USD92
2013-08-01 to 2014-01-31-6,768,946USD184
2005-06-21 to 2014-01-31-41,619,341USD3147
2012-11-01 to 2013-01-31-6,290,158USD92
2012-08-01 to 2013-01-31-7,147,472USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-11-01 to 2014-01-31-5,091,168USD92
2013-08-01 to 2014-01-31-6,630,741USD184
2005-06-21 to 2014-01-31-41,067,898USD3147
2012-11-01 to 2013-01-31-6,241,477USD92
2012-08-01 to 2013-01-31-6,974,522USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-01-31424,678USD
At 2013-07-31619,873USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-11-01 to 2014-01-316,242USD92
2013-08-01 to 2014-01-31131,789USD184
2005-06-21 to 2014-01-31746,223USD3147
2012-11-01 to 2013-01-31109,333USD92
2012-08-01 to 2013-01-31254,754USD184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-01-311,145,526USD
At 2013-07-31883,069USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-11-01 to 2014-01-315,091,168USD92
2013-08-01 to 2014-01-316,630,741USD184
2005-06-21 to 2014-01-3141,067,898USD3147
2012-11-01 to 2013-01-316,241,477USD92
2012-08-01 to 2013-01-316,974,522USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-11-01 to 2014-01-3131,806USD92
2013-08-01 to 2014-01-3189,396USD184
2005-06-21 to 2014-01-31878,235USD3147
2012-11-01 to 2013-01-3174,550USD92
2012-08-01 to 2013-01-31149,691USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-01-31178,206,053shares
At 2013-07-31164,699,973shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-01-3139,739,282USD
At 2013-07-3133,695,679USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2014-01-3122,494USD
At 2013-07-3123,180USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-08-01 to 2014-01-31-6,768,946USD184
2012-08-01 to 2013-07-31-9,177,491USD365
2011-08-01 to 2012-07-31-12,146,447USD366
2010-08-01 to 2011-07-31-11,454,537USD365
2009-08-01 to 2010-07-31-2,016,710USD365
2008-08-01 to 2009-07-3128,444USD365
2007-08-01 to 2008-07-31-17,924USD366
2006-08-01 to 2007-07-31-33,605USD365
2005-08-01 to 2006-07-31-32,125USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-11-01 to 2014-01-315,059,362USD92
2013-08-01 to 2014-01-316,541,345USD184
2005-06-21 to 2014-01-3140,150,648USD3147
2012-11-01 to 2013-01-316,166,927USD92
2012-08-01 to 2013-01-316,824,831USD184

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2013-08-01 to 2014-01-31686USD184
2005-06-21 to 2014-01-314,956USD3147
2012-08-01 to 2013-01-31686USD184

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2013-11-01 to 2014-01-3136,055USD92
2013-08-01 to 2014-01-31-138,205USD184
2005-06-21 to 2014-01-31-551,443USD3147
2012-11-01 to 2013-01-31-48,681USD92
2012-08-01 to 2013-01-31-172,950USD184

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2005-06-21 to 2014-01-313,991,449USD3147

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-08-01 to 2014-01-31-27,715USD184
2005-06-21 to 2014-01-3113,052USD3147
2012-08-01 to 2013-01-314,988USD184

Inspect the source

Entity
OPIANT PHARMACEUTICALS, INC. / CIK 0001385508
Captured
SEC response SHA-256
2364e629461ca2a795db263ee8044ac545282f6ca3e3ea28eb9ce90156d0a955

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385508.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))